arrow
A

Antonino Grassadonia

g d'annunzio university of chieti-pescara
H指数:30
被引数:2,888

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Aerobic Training-Induced Changes in Sedentary Time, Non-Exercise Physical Activity, and Sleep Among Breast Cancer Survivors and Postmenopausal Women Without Cancer

有氧训练对乳腺癌幸存者和无癌症绝经女性静坐时间、非运动身体活动及睡眠的影响

2025-09-290
OAAI
Galectin-3-binding protein is a risk factor for diabetes, metabolic syndrome, and inflammation. Cross-sectional and longitudinal results from the InCHIANTI study

Galectin-3-binding protein是糖尿病、代谢综合征和炎症的风险因素。InCHIANTI研究中的横断面和纵向结果

2025-06-260
OA
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

卡培他滨辅助治疗新辅助治疗后有残留病灶的三阴性乳腺癌患者: 来自CaRe的真实世界证据,一项多中心观察性研究

2023-05-165
OAAI
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Paner研究: 一项来自真实世界环境的HER2-positive晚期乳腺癌患者的多中心观察性研究的20年治疗结果分析

2021-11-296
OAAI
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study

基于MicroRNA的签名影响卵巢癌的临床过程和生物学: 一项miRNOmics研究

2021-07-1313
OAAI
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting

管腔型乳腺癌中性粒细胞与淋巴细胞比值 (NLR) 的预后相关性: 新辅助治疗的回顾性分析

CELLS
IF5.2
2021-07-0324
OAAI
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

ChangeHER试验中转移性乳腺癌HER2-positivity增益的预后相关性

2021-07-026
OAAI
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

抗生素治疗和其他药物对一线pembrolizumab与细胞毒性化疗治疗的非小细胞肺癌患者肿瘤学结局的差异影响

2021-04-0797
OAAI
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study
2020-01-0711
OAAI
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
2019-11-1523
OAAI
Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting

DNA损伤和修复生物标志物在接受新辅助激素治疗的老年激素受体阳性乳腺癌患者中的预后相关性: 来自真实世界的证据

2019-08-182
OAAI
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

不同的HR表达模式显着影响转移性HER2乳腺癌的临床行为以及在现实世界环境中从新型anti-HER2药物中获益的程度

2019-08-075
OAAI